An in vivo barcoded CRISPR-Cas9 screen identifies <i>Ncoa4-</i>mediated ferritinophagy as a dependence in <i>Tet2</i>-deficient hematopoiesis
Abstract
Abstract TET2 is among the most commonly mutated genes in both clonal hematopoiesis and myeloid malignancies; thus, the ability to identify selective dependencies in TET2-deficient cells has broad translational significance. Here, we identify regulators of Tet2 knockout (KO) hematopoietic stem and progenitor cell (HSPC) expansion using an in vivo CRISPR-Cas9 KO screen, in which nucleotide barcoding enabled large-scale clonal tracing of Tet2-deficient HSPCs in a physiologic setting. Our screen identified candidate genes, including Ncoa4, that are selectively required for Tet2 KO clonal outgrowth compared with wild type. Ncoa4 targets ferritin for lysosomal degradation (ferritinophagy), maintaining intracellular iron homeostasis by releasing labile iron in response to cellular demands. In Tet2-deficient HSPCs, increased mitochondrial adenosine triphosphate production correlates with increased cellular iron requirements and, in turn, promotes Ncoa4-dependent ferritinophagy. Restricting iron availability reduces Tet2 KO stem cell numbers, revealing a dependency in TET2-mutated myeloid neoplasms.
Article Details
Authors (14)
Justin Loke
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
Peter G. Kim
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
Thuy T. P. Nguyen
4Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA
Meaghan Boileau
1Dana-Farber Cancer Institute, Department of Pediatric Oncology, Boston, United States
Marie McConkey
Department of Medical Oncology
Aidan Miller
Wesley Shin
1Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, United States
Christopher B. Hergott
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
Maria Ericsson
Blavatnik Institute, Harvard Medical School
Anja Nordstrom
7Department of Cell Biology, Harvard Medical School, Boston, MA
Paula Montero Llopis
8MicRoN Core, Harvard Medical School, Boston, MA
Scott A. Armstrong
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA.
Joseph D. Mancias
Benjamin L. Ebert
Department of Medical Oncology